Acceptys Inc.
This article was originally published in Start Up
Executive Summary
With an engineered cell line, Acceptys can capture, screen and produce naturally occurring human antibodies ex vivo.
You may also be interested in...
Therapeutic Antibody Start-Ups
After more than a decade of anticipation, pharmas have now clearly recognized the value of antibodies as therapeutics. And biotechs can offer discovery tools and development expertise.
Who's Got Game in Antibody Development?
The handful of firms with established bioprocessing capabilities has dominating advantages in antibody drug development. Because process varies little from one antibody to another, they can wait for and quickly pounce on fast-follower opportunities, expanding production capacity in a modular fashion as demand requires--and in this way minimize target risk. Meanwhile, smaller companies, which cannot buy their way into the game nor compete in the more mature world of fast followers, are using their technology development expertise to come up with good drugs against novel targets in diseases where no antibody treatments currently exist, hoping that the novelty of the resulting products will give them the kind of leverage they haven't been able to get from platform dealmaking.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.